Aurinia to stop development of immunotherapies after strategic review, ET HealthWorld

[ad_1]

Bengaluru: Aurinia Pharmaceuticals will stop research and development on its immunotherapies to focus on its kidney disease drug Lupkynis after failing to attract a formal buyout offer, the company said on Thursday.

The Canada-based drugmaker said it had failed to attract a formal offer after it had embarked on a strategic review it launched at the end of June, confirming a Reuters report from earlier in the day.

Aurinia anticipates reducing employee headcount by at least 25% by the end of the first quarter of 2024.

The company also initiated a share repurchase program of up to $150 million.

  • Published On Feb 15, 2024 at 06:26 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles


Scan to download App


[ad_2]

Leave a Reply

Your email address will not be published. Required fields are marked *